RESUMEN
INTRODUCTION: Opsoclonus-myoclonus-ataxia (OMA) syndrome is a rare neurological disorder characterized by involuntary conjugate saccadic eye movements, myoclonus, and ataxia. Few reports exist on patients with HIV and OMA. CASE REPORT: A 41-year-old man diagnosed with HIV-1 infection in 1997 coursed with multiple anti-retroviral schemes as a consequence of poor adherence. In 2008 he presented an HIV-1 viral load of 100,000 copies/mL and a CD4+ T cell count of 10 cells/mm3. In 2013 our patient arrived with an 11-month history of progressive opsoclonus and ataxia. He had undetectable plasma HIV-1 RNA load and CD4+ of 606 cells/mm3. No opportunistic infections were found. Cerebrospinal fluid analysis showed mildly elevated protein concentration and HIV-1 viral load of 534 copies/mL. Cerebrospinal fluid co-receptor tropism test showed selective CCR5 usage. A brain magnetic resonance imaging showed hippocampal atrophy and T2-weighted hyperintensities. Our patient exhibited a dramatic recovery and cerebrospinal fluid HIV clearance after adjustment of anti-retroviral treatment based on genotyping resistance and tropism analyses. CONCLUSIONS: In patients with HIV presenting cengral nervous system dysfunction without opportunistic infections, cerebro-spinal fluid and plasma HIV-1 viral load, resistance and tropism tests should be performed to assess a potential viral escape and to design the appropriate anti-retroviral therapy in an individual patient basis.
TITLE: Síndrome opsoclono-mioclono-ataxia asociado a fenómeno de escape viral por virus de la inmunodeficiencia humana en el sistema nervioso central.Introducción. El síndrome opsoclono-mioclono-ataxia (OMA) es un trastorno neurológico infrecuente caracterizado por movimientos oculares conjugados sacádicos involuntarios, mioclonías y ataxia. Existen pocos casos en la bibliografía de pacientes con virus de la inmunodeficiencia humana (VIH) y OMA. Caso clínico. Varón de 41 años y diagnóstico de infección por el VIH-1 desde 1997, que cursó con múltiples esquemas antirretrovirales debido a una pobre adhesión al tratamiento. En 2008 presentó una carga viral de 100.000 copias/mL y una cuenta linfocitaria CD4+ de 10 células/mm3. En 2013 sufrió un cuadro progresivo de 11 meses de evolución caracterizado por opsoclonía y ataxia. En ese momento, su carga viral era indetectable, y la cuenta de CD4+, de 606 células/mm3. Se descartaron infecciones oportunistas. El examen del líquido cefalorraquídeo demostró hiperproteinorraquia leve y una carga viral de 534 copias/mL. El examen del tropismo de correceptor en el líquido cefalorraquídeo demostró un uso selectivo de CCR5. La resonancia magnética cerebral objetivó atrofia hipocámpica e hiperintensidades en las secuencias ponderadas en T2. El paciente mostró una recuperación clínica franca y un aclaramiento de la carga viral en el líquido cefalorraquídeo tras el ajuste de antirretrovirales basado en la resistencia de genotipo y el análisis de tropismo. Conclusiones. En pacientes con infección por el VIH y disfunción del sistema nervioso central sin infecciones oportunistas, debería llevarse a cabo una determinación de la carga viral en el plasma y el líquido cefalorraquídeo para descartar un potencial fenómeno de escape viral, así como exámenes de resistencia y tropismo para diseñar el tratamiento antirretroviral adecuado.
Asunto(s)
Infecciones por VIH , Síndrome de Opsoclonía-Mioclonía , Adulto , Ataxia , Infecciones por VIH/complicaciones , Humanos , Imagen por Resonancia Magnética , Masculino , Síndrome de Opsoclonía-Mioclonía/complicaciones , Síndrome de Opsoclonía-Mioclonía/diagnóstico por imagen , Síndrome de Opsoclonía-Mioclonía/virología , Carga ViralRESUMEN
OBJECTIVES: Early initiation of antiretroviral therapy (ART) during acute HIV infection is associated with favourable clinical and epidemiological outcomes. Barriers to prompt treatment initiation limit the benefits of universal access to ART in Mexico. We sought to create an algorithm for the immediate detection and treatment of patients with acute HIV infection. METHODS: A nationwide cohort of patients with acute HIV infection was created in 2015. In order to identify cases and treat them promptly at our centre, an interdisciplinary group coordinated through an instant-messaging tool using smart phones was established. When a probable case was detected, a discussion was initiated to confirm the diagnosis and facilitate the administrative processes to initiate ART as soon as possible. We compared time to ART initiation with that in a comparison group of patients with chronic HIV infection enrolled during the same period (May 2015 to February 2017) through routine care, using survival analysis estimators and log-rank tests. RESULTS: We recruited 29 patients with acute HIV infection. The median time to ART initiation was 2 days in these patients, in contrast to 21 days for patients with chronic infection. There were no significant differences in the percentages of patients engaged in care, on treatment or virologically suppressed at 1 year of follow-up. CONCLUSIONS: Implementing immediate ART initiation programmes is feasible in Mexico, in spite of the substantial administrative barriers that exist in the country. More extensive replication of this model in other centres and in patients with chronic infection is warranted to evaluate its effect on the continuum of care.
Asunto(s)
Fármacos Anti-VIH/administración & dosificación , Infecciones por VIH/tratamiento farmacológico , Adulto , Algoritmos , Fármacos Anti-VIH/uso terapéutico , Estudios de Cohortes , Femenino , Humanos , Masculino , México , Persona de Mediana Edad , Relaciones Médico-Paciente , Teléfono Inteligente , Análisis de Supervivencia , Centros de Atención Terciaria , Tiempo de Tratamiento , Resultado del TratamientoAsunto(s)
Equinococosis/diagnóstico por imagen , Leucemia de Células Pilosas/complicaciones , Bazo/patología , Albendazol/uso terapéutico , Animales , Anticestodos/uso terapéutico , Equinococosis/tratamiento farmacológico , Humanos , Huésped Inmunocomprometido , Leucemia de Células Pilosas/parasitología , Hígado/diagnóstico por imagen , Hígado/parasitología , Pulmón/diagnóstico por imagen , Pulmón/parasitología , Masculino , Persona de Mediana Edad , Radiografía Torácica , Bazo/parasitología , Tomografía Computarizada por Rayos XRESUMEN
The effect of extracellular HIV Nef (exNef) protein on the induction of lytic activity and proliferation of CD8+T lymphocytes from 18 donors was studied. At 10 ng/ml, exNef-induced a 2- to 8-fold enhancement of basal lytic activity in cells from all donors in an allogeneic induction assay, whereas it was ineffective at 100ng/ml. The extent of enhancement was inversely correlated with the basal level of lytic activity without exNef. Only in combination with PHA did both exNef concentrations stimulate proliferation, and in a manner inversely related to the effect of PHA alone. Thus, concentrations of exNef commonly found in sera of HIV-infected patients were found to modulate the induction of lytic activity and proliferation of CD8+ T lymphocytes in vitro, to an extent strongly dependent on the quite variable responsiveness of each donor. These findings point to Nef as a potential agent for modulating CD8+ T cell function in pathogenesis and therapy.
Asunto(s)
Linfocitos T CD8-positivos/efectos de los fármacos , Productos del Gen nef del Virus de la Inmunodeficiencia Humana/farmacología , Apoptosis , Linfocitos T CD8-positivos/inmunología , Proliferación Celular , Células Cultivadas , Relación Dosis-Respuesta a Droga , Espacio Extracelular/metabolismo , Femenino , Humanos , MasculinoRESUMEN
BACKGROUND: We have previously shown that the prevalence of hepatitis associated with the hepatitis C virus (HCV) in patients with end stage renal disease in our institution is 10.2%. However, quantification of viral RNA in plasma and its relation with clinical variables has never been studied in our patients. Thus, the aim of the present work was to quantify the HCV viral load in patients with ESRD in dialysis, and to correlate these values with the dialysis modality and the viral genotype. METHODS: We performed a transverse, prospective and comparative study in patients with HCV infection in hemodialysis, continuous ambulatory peritoneal dialysis and patients in peritoneal dialysis, but with history of hemodialysis. Viral load was quantified with RT-PCR by using a commercial kit known as Amplicor HCV 2.0. Clinical variables studied were: age, gender, end stage renal disease etiology, modality and time in dialysis, transfusions, serum albumin, aminotransferases, blood urea nitrogen, and serum creatinine. RESULTS: Twenty four patients in dialysis with HCV infection entered into the study. Of these patients, 25% were on peritoneal dialysis, 29% on peritoneal dialysis with history of hemodialysis, and 46% were in hemodialysis. The average viral load (copies x 10(6)/mL) was 1.41 +/- 3.01. Viral load was lower in patients on peritoneal dialysis than in patients treated, or with history of hemodialysis (0.20 +/- 0.12 vs 2.04 +/- 0.88; p < 0.05). We observed no differences in viral load among patients with different viral genotypes. DISCUSSION: The average viral load of our patients in dialysis is lower than the levels usually observed in hepatitis C infected patients without end stage renal disease. The lower viral load in patients treated with peritoneal dialysis, and no history of hemodialysis, probably denotes lower risk of chronic liver disease in these subpopulation.
Asunto(s)
Hepacivirus/aislamiento & purificación , Hepatitis C/epidemiología , Fallo Renal Crónico/complicaciones , Adulto , Anciano , Estudios Transversales , Femenino , Genotipo , Hepacivirus/clasificación , Hepacivirus/genética , Hepatitis C/complicaciones , Hepatitis C/transmisión , Hepatitis C/virología , Humanos , Fallo Renal Crónico/terapia , Pruebas de Función Hepática , Masculino , México/epidemiología , Persona de Mediana Edad , Diálisis Peritoneal Ambulatoria Continua/efectos adversos , Prevalencia , Estudios Prospectivos , ARN Viral/genética , ARN Viral/aislamiento & purificación , Diálisis Renal/efectos adversos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Reacción a la Transfusión , Carga Viral , Viremia/epidemiología , Viremia/virologíaRESUMEN
The last pandemia of the century, that of the Acquired Immunodeficiency Syndrome (AIDS) caused by the Human Immunodeficiency Virus (HIV), continues to advance with gigantic steps at about 18,000 new infections per day worldwide. In the last four years, breakthroughs have been achieved and new medications have been introduced, which have impacted the progression of HIV and its disease, decreasing associated morbidity and mortality. During the course of infection, HIV replicates actively producing as much as 10(10) genetically different virions (quasi-species), which relates to immune escape, higher pathogenicity and drug resistance. Persistent viral replication causes T CD4+ cell destruction and immunodeficiency through several mechanisms. Currently, there are 14 approved anti-retrovirals that when used as triple regimens have been able to decrease opportunistic infections, hospitalization and mortality rates. Unfortunately, these regimens still have many limitations, do not cure and can only suppress the virus effectively in 50% of the treated patients. Besides, when they are inadequately used there is associated resistance development. On the other hand, indications for treatment initiation are changing continuously and heading towards a conservative approach. In the case of salvage regimens, there are only general guidelines that have not been evaluated in clinical studies. Resistance assays have great limitations and their use is very specific. All these factors have made antiretroviral treatment a very complicated issue that should be prescribed and followed by an expert.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida/fisiopatología , Síndrome de Inmunodeficiencia Adquirida/etiología , Síndrome de Inmunodeficiencia Adquirida/inmunología , Adulto , Fármacos Anti-VIH/uso terapéutico , Resistencia a Medicamentos , Humanos , Cooperación del PacienteRESUMEN
The frequency of Nocardia infection in HIV-infected patients has increased during the past few years from 0.3% in 1985 to 1.8% in 1989. Although it is not of great concern as an AIDS-associated infection, the nonspecific clinical presentation in these patients might be confused with other lung infections such as tuberculosis (TB). The mortality rate can be as high as 60%. The authors diagnosed three homosexual men with nocardiasis among 1060 HIV-infected patients (0.2%) in a tertiary care center in Mexico City from 1981 to 1997. The mean age was 32 years. The CD4 count was less than 260 cells/mm3 in all these individuals. The clinical presentations were subacute sinusitis, chronic localized abdominal abscess, and acute disseminated nocardiasis. The respective associated infections were none; TB and cytomegalovirus (CMV); and candidiasis, TB, CMV, Isospora belli, and disseminated Mycobacterium avium complex (MAC). Trimethoprim/sulfamethoxazole (TMP/SMX) was the treatment in all the cases; at the time of this writing, two patients were living and one had died during the acute episode. A literature search uncovered 130 cases of Nocardia infection in HIV patients since 1982. According to the published data and our results, nocardiasis should be suspected in those HIV-infected patients who (1) do not respond to appropriate antituberculous treatment; (2) are intravenous drug users; and (3) develop a characteristic pericardial infection. Finally, adequate surgical or percutaneous drainage of abscesses are extremely valuable for diagnosis and therapy.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/diagnóstico , Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Antiinfecciosos/uso terapéutico , Nocardiosis/diagnóstico , Nocardiosis/tratamiento farmacológico , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico , Adolescente , Adulto , Anciano , Niño , Femenino , Homosexualidad Masculina , Humanos , Masculino , Persona de Mediana Edad , PronósticoRESUMEN
AIDS: At the 12th World AIDS Conference in Geneva many sessions discussed the reality that although AIDS treatment has made major advances, it remains financially out of reach for most of the world's population. Since the Vancouver conference, an additional 10 million people have become infected with HIV. A chart shows the prevalence of AIDS by continent. While many believe a reliable and affordable vaccine is the answer, none of the vaccines under development appear very effective. Other sessions at the conference discussed preventing perinatal transmission, the status of highly active antiretroviral therapy research, viral resistance, and results of studies on tuberculosis, STDs, and other opportunistic infections.^ieng
Asunto(s)
Vacunas contra el SIDA , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/prevención & control , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Infecciones Oportunistas Relacionadas con el SIDA/epidemiología , Infecciones Oportunistas Relacionadas con el SIDA/prevención & control , Animales , Fármacos Anti-VIH/uso terapéutico , Ensayos Clínicos como Asunto , Congresos como Asunto , Farmacorresistencia Microbiana , Femenino , Infecciones por VIH/epidemiología , Humanos , Recién Nacido , Masculino , Programas de Intercambio de Agujas , Embarazo , Suiza , Zidovudina/uso terapéuticoRESUMEN
The human immunodeficiency viruses (HIV-1) undergo high rates of variation. Only a few point mutations in the envelope gene are required to switch the tropism of HIV-1 from a growth preference for monocytes to lymphocytes or to acquire lytic properties for rapid killing of infected T4 lymphocytes. Since heterosexual transmission efficiency is high for HIV-1's that are most prevalent in Africa or Asia, but low for HIV-1 B, which dominates in the US and western Europe, we asked whether African and Asian viruses had a particular tropism for cells of the reproductive tract. Langerhans' cells (LC), showed only minimal susceptibility to infection with HIV-1B from the US, but substantially greater sensitivity for infections by HIV-1 E and HIV-1 C, subtypes that predominate in Asia and Africa.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/transmisión , Genes env , Variación Genética , VIH-1/genética , Síndrome de Inmunodeficiencia Adquirida/epidemiología , África , Asia , Susceptibilidad a Enfermedades , Europa (Continente) , Femenino , VIH-1/patogenicidad , VIH-1/fisiología , Humanos , Masculino , Mutación Puntual , Conducta Sexual , Estados Unidos , VirulenciaAsunto(s)
Tuberculosis/tratamiento farmacológico , Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Adulto , Antibacterianos , Antibióticos Antituberculosos/administración & dosificación , Antibióticos Antituberculosos/uso terapéutico , Antituberculosos/administración & dosificación , Antituberculosos/uso terapéutico , Ensayos Clínicos como Asunto , Quimioterapia Combinada/administración & dosificación , Quimioterapia Combinada/uso terapéutico , Humanos , Factores de Tiempo , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológicoRESUMEN
HIV-1 isolates are classified phylogenetically in several subtypes or clades according to env and gag coding sequences. Viral subtypes tend to cluster geographically. DNA sequences encoding the p51 subunit of reverse transcriptase were obtained by nested polymerase chain reaction from peripheral blood mononuclear cells of two HIV-1-seropositive individuals from New Delhi and three from Pune, in northern and western India, respectively. These isolates were previously characterized as subtype C according to their env sequences. Based on phylogenetic analysis, the reverse transcriptase coding region of these isolates is distinct from those of subtype A, subtype B, subtype D, and group O of HIV-1 viruses. The nucleotide divergence of these Indian pol sequences (3.3%) is similar to that of existing sequences for subtype B and subtype D viruses. This result supports the epidemiologic data of a more recently introduced HIV-1 epidemic in India. Based on the corresponding env sequences, the pol sequences described in this report are subtype C.
Asunto(s)
Genes pol/genética , Seropositividad para VIH/genética , VIH-1/genética , Secuencia de Aminoácidos , Secuencia de Bases , Cartilla de ADN , ADN Viral/análisis , Transcriptasa Inversa del VIH/genética , Seropositividad para VIH/epidemiología , Seropositividad para VIH/virología , VIH-1/clasificación , VIH-1/aislamiento & purificación , Humanos , India/epidemiología , Datos de Secuencia Molecular , Filogenia , Reacción en Cadena de la PolimerasaRESUMEN
Heterosexual transmission by vaginal intercourse accounts for most transmission of human immunodeficiency virus-type 1 (HIV-1) in Africa and Asia but is less important in the HIV-1 epidemics of the United States and Western Europe. Epithelial Langerhans' cells (LCs) represent a possible source of initial cell contact for vaginal infection. Fifteen primary isolates of HIV-1 from U.S. homosexuals and 18 HIV-1 isolates from Thailand heterosexuals were evaluated for growth in LCs of U.S. origin. All the viruses from the Thai heterosexuals, which were subtype E, grew more efficiently in the LCs than any of the viruses from the U.S. homosexuals, which are subtype B. These results suggest that LC tropism is associated with the efficiency of heterosexual transmission of HIV.
Asunto(s)
Infecciones por VIH/transmisión , VIH-1/crecimiento & desarrollo , Células de Langerhans/virología , Conducta Sexual , Enfermedades Virales de Transmisión Sexual/transmisión , Línea Celular , Células Cultivadas , Proteína p24 del Núcleo del VIH/análisis , Infecciones por VIH/virología , VIH-1/clasificación , VIH-1/aislamiento & purificación , Homosexualidad Masculina , Humanos , Macrófagos/virología , Masculino , Monocitos/virología , Enfermedades Virales de Transmisión Sexual/virología , Linfocitos T/virología , Tailandia , Estados Unidos , Replicación ViralRESUMEN
Despite the likely role of mucosae in human T cell leukemia virus type I (HTLV-I) transmission, little is known about the mucosal immune response to HTLV-I. The present study evaluated the antibody response to HTLV-I in oral mucosa and the value of crevicular fluid rich saliva (CFRS) for diagnosing HTLV-I infection. CFRS and sera from patients with tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM), asymptomatic carriers, and HTLV-I seronegative individuals from Tumaco, Colombia, were analyzed for HTLV-I specific IgG, IgA, and secretory IgA (sIgA). Detection of IgG in CFRS by enzyme-linked immunosorbent assay correlated with its presence in sera for TSP/HAM patients and asymptomatic carriers. IgA and sIgA were more frequently detected in CFRS and sera from TSP/HAM patients than in those from asymptomatic carriers. An HTLV-I pol fragment could be amplified from CFRS by reverse transcriptase-PCR in 3 TSP/HAM patients and one asymptomatic carrier, all of whom had an IgA response in CFRS but not in sera. The more frequent detection of IgA and sIgA in sera and CFRS of TSP/HAM patients suggests increased viral replication. Further, the association of viral RNA in CFRS with a local IgA response may signify rounds of viral replication in the oral cavity.
Asunto(s)
Especificidad de Anticuerpos/inmunología , Líquido del Surco Gingival/inmunología , Anticuerpos Anti-HTLV-I/análisis , Virus Linfotrópico T Tipo 1 Humano/genética , Virus Linfotrópico T Tipo 1 Humano/inmunología , Paraparesia Espástica Tropical/inmunología , ARN Viral/análisis , Saliva/inmunología , Ensayo de Inmunoadsorción Enzimática , Líquido del Surco Gingival/virología , Anticuerpos Anti-HTLV-I/sangre , Humanos , Paraparesia Espástica Tropical/sangre , Paraparesia Espástica Tropical/diagnóstico , Reacción en Cadena de la Polimerasa , Saliva/virología , Streptococcus mutans/inmunologíaRESUMEN
The purpose of this open and multicenter trial was to determine the usefulness of antibody detection by enzyme-linked immunosorbent assay (ELISA) in gingival crevicular transudate (GCT), which was collected with an investigational device (Orasure; Epitope, Beaverton, Oreg.), for the diagnosis of human immunodeficiency virus type 1 (HIV-1) infection and to compare it with antibody detection in serum. A total of 1,880 individuals were tested, as follows: 354 HIV-1-infected individuals (111 asymptomatics individuals and 243 individuals with AIDS), 46 individuals with autoimmune diseases (AD), 296 individuals with dental diseases, 42 individuals with other chronic diseases, and 1,142 healthy individuals. Sera from 356 individuals and GCT from 354 individuals were positive for HIV-1 antibodies. There were two false-negative gingival samples, one from an HIV-1-positive asymptomatic individual and one from a patient with AIDS. HIV-1 antibodies were unexpectedly detected in both serum and GCT of two individuals, one with dental disease and one with pulmonary tuberculosis. None of the sera or GCTs from healthy subjects or patients with AD were positive. Compared with the serum assay, the sensitivity, specificity, and positive and negative predictive values of the GCT assay were 99.5, 100, 100, and 99.9%, respectively. Of 355 paired serum-GCT samples that were HIV-1 positive by ELISA and that were tested by Western blot (immunoblot), all were positive for HIV-1 by using the U.S. Public Health Service interpretation criteria, while among gingival samples, 301 were positive, 52 were indeterminate, and 2 were negative. Of 82 negative paired samples selected at random, 80 were negative by Western blotting of serum and GCT and 2 were indeterminate by Western blotting of serum and negative by Western blotting of GCT (a healthy blood donor and a patient with dermatopolymyositis). Testing for HIV-1 antibodies in GCT is a simple and reliable screening procedure in populations with high and low prevalences of infection because of the high sensitivity and specificity of the method, and it offers improved safety for hospital personnel.